CRISPR-Chip – one of the Cardean Transistor versions allowing for biology’s signals (here DNA) to be read directly by computers.
In the News
Cardean Transistors™ made available to companies and government agencies willing to build handheld Coronavirus detection devices
Our handheld technology has the capability to do rapid virus detection at any location – making the “invisible” coronavirus visible to everybody over the Internet. Quote from our CEO, Michael Heltzen: “We strongly believe that we are holding a critical component to combat the current, but also future, virus attacks. Having said that, we need the support of large companies and government organizations to get this new type of technology in the hands of the masses.”READ THE PRESS RELEASE
We have partnered up with COBO Technologies to bring solutions to challenges with the precision of genome editing. We will together co-develop and market a portfolio of CRISPR QC products and services for quality control (QC) of CRISPR research, agricultural, and pre-clinical programs. Over the longer-term, we aim to develop a COBO branded QC device based on Cardea’s CRISPR-Chip QC technology for use before and after genome-editing in the pre-clinical setting.
READ THE PRESS RELEASE
READ THE PRESS RELEASE
Want to be one of the first in the world to google a genome? We’ve merged with our partner-company, Nanosens, to accelerate the launch of the Genome Sensor™, the world’s first DNA Search Engine. Read the article written by Genome Web’s reporter, Christie Rizk, to find out how you can become one of the select few to be a part of the Genome Sensor Early Access Program.
READ THE PAPER
READ THE PAPER
Christie Rizk from Genome Web interviewed our CEO, Michael Heltzen about how CRISPR-Chip can be applied to far more industries than just clinical research. Quote from the article: “The advantage to this technology approach, Heltzen said, is that it allows a researcher to observe DNA in its natural state, without the need for amplification and optical instruments. Instead of breaking down the DNA, amplifying it, labeling it, and then shining an optical laser on it in order to read it (or as Heltzen puts it, “running it over with a bus three times”), the graphene-based chips are able to read the DNA in its native state and very quickly signal whether or not a specific mutation, protein, or other component is present.”.READ THE PAPER
Molly Campbell, writer for Technology Networks, interviewed our CEO, Michael Heltzen, to hear his thoughts about our recent merge with our partner company, Nanosens, and gives insight to CRISPR-Chip technology.READ THE PAPER
An independent research group from Laboratory for Sensors, Department of Microsystems Engineering (IMTEK), University of Freiburg in Germany was asked by Nature BME to give their independent perspectives on the CRISPR-chip in the June issue. Quote from the article: “In view of the growing demand for portable devices for molecular diagnostics, future versions of the CRISPR-chip might offer an easy-to-handle, versatile and rapid on-chip solution for genome-based diagnostics”.READ THE PAPER
Nature BME’s editorial (by Pep Pàmies, Chief Editor) points out CRISPR-Chip’s innovative technology and design to enable new biomedically readouts from samples is going to be key if we want to have breakthroughs for diagnostics (including human, plant, animal, bacteria, virus).READ THE PAPER
Detection of unamplified target genes via CRISPR–Cas9 immobilized on a graphene field-effect transistor – Nature BME
Kiana Aran, CEO of Nanosens and innovator of the CRISPR-Chip, shows how CRISPR-Chip can scan through a human genome, looking for a gene with a specific gene mutation in a clinical sample – in just 15 minutes.READ THE PAPER
Written by Kara Manke, Berkeley, the article presents how the CRISPR-dcas9 protein can unzip double-stranded DNA and scan through until it finds the sequence that matches the guide RNA, and then latch on.READ THE PAPER
Julianna LeMieux, Gen ENG writer, shares how CRISPR-Chip can search for specific genetic mutations, such as Duchenne muscular dystrophy (DMD), and bind to its target sequence in a matter of minutes.READ THE PAPER
Podcasts & Webinars
Michael Heltzen, CEO of Cardea, and Brett Goldsmith, CTO of Cardea.LISTEN TO PODCAST
Kiana Aran, CEO of Nanosens.LISTEN TO PODCAST
Brett Goldsmith, Cardea’s CTO, was interviewed about our company, all the work that has been put into it, and the Internet of biology revolution.LISTEN TO PODCAST
Brett Goldsmith, CTO of Cardea gives a presentation about the technology that is the foundation of our company, enabling the Internet of Biology to exist.LISTEN TO PODCAST